TRIPROLIDINE
Actahist, Actidil, Actifed, Allerfed, Corphed, Histafed, Myfed, Myidyl, Trilitron, Triphed (triprolidine) is a small molecule pharmaceutical. Triprolidine was first approved as Triprolidine hydrochloride on 1982-01-01. It is used to treat allergic conjunctivitis, atopic dermatitis, and rhinitis in the USA. The pharmaceutical is active against histamine H1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Codeine phosphate
+
Pseudoephedrine hydrochloride
+
Triprolidine hydrochloride
Pseudoephedrine hydrochloride
+
Triprolidine hydrochloride
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| actifed | OTC monograph final | 2023-08-01 |
| cold and flu | C200263 | 2023-12-26 |
| corphedra | New Drug Application | 2018-10-17 |
| cvs maximum strength severe congestion and cough | OTC monograph final | 2020-04-13 |
| cvs mucus relief dm and overnight cold and flu | OTC monograph final | 2023-09-12 |
| cvs nighttime cold and flu | OTC monograph final | 2023-09-13 |
| cvs overnight cold and flu clear and cool | OTC monograph final | 2023-09-13 |
| delsym nighttime cough | OTC monograph final | 2023-02-27 |
| endal | unapproved drug other | 2024-01-27 |
| flonase | C200263 | 2023-11-16 |
Show 34 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TRIPROLIDINE |
| INN | triprolidine |
| Description | Triprolidine is an N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders. It has a role as a H1-receptor antagonist. It is a N-alkylpyrrolidine, a member of pyridines and an olefinic compound. It is a conjugate base of a triprolidine(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 486-12-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL855 |
| ChEBI ID | 84116 |
| PubChem CID | 5282443 |
| DrugBank | DB00427 |
| UNII ID | 2L8T9S52QM (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Triprolidine
+
Phenylephrine
+
Codeine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Triprolidine
+
Dextromethorphan
+
Phenylephrine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Triprolidine
+
Pseudoephedrine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Triprolidine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 715 documents
View more details
Safety
Black-box Warning
Black-box warning for: Triacin-c
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
387 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use